Patheon opens new drug development suite

By Gareth Macdonald

- Last updated on GMT

Related tags Good manufacturing practice Pharmacology

Patheon hopes that a new pharmaceutical development services (PDS) suite at its facility in Whitby, Ontario will complete its “Quick to Clinic” offering and provide a rapid-response means of making solid dosage forms for trials.

The 2,500 square foot unit will house good manufacturing practice (GMP) compliant production lines capable of making drug supplies for Phase I and II clinical trials. The facility will also provide early-phase manufacturing capacity in the 1kg to 10kg range.

The PDS also houses multiple laboratory units capable of carrying out small scale dosage testing, powder-in-bottle manufacture, as well as tablet, capsule, oral dosage and nasal spray development.

A statement issued by PDS' vice president, Colin Minchom, detailed some of the unit’s potential advantages. He singled out the PDS’ “rapid response capabilities​” as being a feature that will: “significantly strengthen Patheon’s competitiveness in the pharmaceutical and biotechnology early development area​.”

Patheon’s president of North American operations, Terry Novak, added the firm “is committed to investing in its development services business and with this new capacity in Whitby; we can now offer rapid early phase development to our North American customers.”

Further evidence of Patheon’s efforts to develop its offering emerged earlier this month when the firm opened a new intermediate scale processing suite (ISPS) at its plant in Cincinnati, US.

In contrast with the PDS, the ISPS will focus on helping drugmakers to scale-up processes according to US Food and Drug Administration (FDA) quality by design (QbD) principles.

Related topics Clinical Development Phase I-II

Related news

Show more

Related products

show more

Using Define-XML to build more efficient studies

Using Define-XML to build more efficient studies

Content provided by Formedix | 14-Nov-2023 | White Paper

It is commonly thought that Define-XML is simply a dataset descriptor: a way to document what datasets look like, including the names and labels of datasets...

Overcoming rapid growth challenges with process liquid preparation

Overcoming rapid growth challenges with process liquid preparation

Content provided by Thermo Fisher Scientific - Process Liquid Preparation Services | 01-Nov-2023 | Case Study

A growing contract development manufacturing organization (CDMO) was challenged with the need to quickly expand their process liquid and buffer preparation...

Why should you use clinical trial technology?

Why should you use clinical trial technology?

Content provided by Formedix | 01-Nov-2023 | White Paper

New, innovative clinical trial technology is helping to revolutionize the research landscape. COVID-19 demonstrated that clinical trials can be run much...

Related suppliers

Follow us


View more